RxDoctor Payments Data

Emanuel Wurm, DO

Pulmonary Disease · White Plains, NYNPI 1619940467

Payments from drug & device makers

$268in general payments, 2019–2025

Across 23 payments — averaging $11.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$119
  • Electromed, Inc.$93
  • Verona Pharma, Inc.$40
  • GSK$16

What the payments were for

  • Food & beverage$268100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$119
Electromed, Inc.19$93
Verona Pharma, Inc.2$40
GSK1$16

How this compares

$268 in reported general payments places this provider in the 30th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$166,360
Medicare patients
427
Services billed
1,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breo ElliptaFluticasone/Vilanterol189$123,873
Arnuity ElliptaFluticasone Furoate407$121,282
Advair HfaFluticasone Propion/Salmeterol225$116,157
Trelegy ElliptaFluticasone/Umeclidin/Vilanter133$106,692
Incruse ElliptaUmeclidinium Bromide140$62,624
SymbicortBudesonide/Formoterol Fumarate145$55,222
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr55$38,630
Spiriva RespimatTiotropium Bromide30$32,497
Combivent RespimatIpratropium/Albuterol Sulfate40$30,191
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate109$24,961
Spiriva HandihalerTiotropium Bromide29$22,438
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$21,538
Albuterol Sulfate HfaAlbuterol Sulfate707$19,991
Fluticasone-SalmeterolFluticasone Propion/Salmeterol121$14,880
Tiotropium Bromide19$14,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta, Arnuity Ellipta, Trelegy Ellipta, Incruse Ellipta, Anoro Ellipta$16$453,101924 claims
AstraZenecaSymbicort, Breztri Aerosphere, Pulmicort Flexhaler$119$83,128196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →